High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2020.03.005
Abstract: Abstract Introduction Actionable somatic molecular alterations are found in 15% to 20% of NSCLC in Europe. NSCLC is a tumor observed in patients with germline TP53 variants causing Li-Fraumeni syndrome (LFS), but its somatic molecular… read more here.
Keywords: somatic oncogenic; tp53 variants; patients nsclc; oncogenic driver ... See more keywords
A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-10770-8
Abstract: As lung cancer has increased to the most common cause of cancer death worldwide, prognostic biomarkers and effective targeted treatments remain lacking despite advances based on patients’ stratification. Multiple core cyclins, best known as drivers… read more here.
Keywords: lung cancer; oncogenic driver; new oncogenic; cancer ... See more keywords
Abstract 5867: Identification of novel inhibitors of the PAX3-FOXO1 oncogenic driver in rhabdomyosarcoma
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-5867
Abstract: Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood, representing 8% of all childhood tumors. The most aggressive subtype of RMS is associated with chromosomal translocations creating a fusion transcription factor, most… read more here.
Keywords: rhabdomyosarcoma; pax3 foxo1; foxo1 oncogenic; oncogenic driver ... See more keywords
Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland
Sign Up to like & getrecommendations! Published in 2019 at "Diagnostic Pathology"
DOI: 10.1186/s13000-019-0789-1
Abstract: BackgroundMolecular testing of lung adenocarcinoma for oncogenic driver mutations has become standard in pathology practice. The aim of the study was to analyze the EGFR, KRAS, ALK, RET, ROS1, BRAF, ERBB2, MET and PIK3CA mutational… read more here.
Keywords: lung adenocarcinoma; status; patients lung; pathology ... See more keywords
Meta-analysis exploring the effect of oncogenic driver mutations on outcome of metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI) or docetaxel (doc).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.9029
Abstract: 9029Background: Recent reports suggest that pts with mNSCLC with tumor EGFR mutations (EGFRm) receiving ICI as second line-plus (2L+) therapy may have better clinical outcomes with doc compared to ICI. We aimed to further investigate… read more here.
Keywords: analysis; effect; oncogenic driver; driver mutations ... See more keywords